BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30191677)

  • 21. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.
    Dorfman DM; Brown JA; Shahsafaei A; Freeman GJ
    Am J Surg Pathol; 2006 Jul; 30(7):802-10. PubMed ID: 16819321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of PDGFRA and CMYC in extranodal NK/T-cell lymphoma and their prognostic implications].
    Chen YP; Zhu WF; Lin JY; He TM; Ma HM; Lu JP; Ye XA; Xu CW; Chen G
    Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):825-830. PubMed ID: 28056296
    [No Abstract]   [Full Text] [Related]  

  • 23. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
    Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
    Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.
    Martin P; Furman RR; Rutherford S; Ruan J; Ely S; Greenberg J; Coleman M; Goldsmith SJ; Leonard JP
    Leuk Lymphoma; 2015; 56(11):3065-70. PubMed ID: 25754579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies.
    Tsuboi K; Iida S; Inagaki H; Kato M; Hayami Y; Hanamura I; Miura K; Harada S; Kikuchi M; Komatsu H; Banno S; Wakita A; Nakamura S; Eimoto T; Ueda R
    Leukemia; 2000 Mar; 14(3):449-56. PubMed ID: 10720141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the serpin centerin defines a germinal center phenotype in B-cell lymphomas.
    Paterson MA; Hosking PS; Coughlin PB
    Am J Clin Pathol; 2008 Jul; 130(1):117-26. PubMed ID: 18550480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type.
    Lo Bello G; Akarca AU; Ambrosio MR; Agostinelli C; Molina-Kirsch H; Ramsay A; Rodriguez-Justo M; Pugh M; Zhao S; DeLisser M; Sabattini E; Dojcinov S; Pileri SA; Natkunam Y; Leoncini L; Marafioti T
    Virchows Arch; 2018 Dec; 473(6):749-757. PubMed ID: 30151671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.
    Moore EM; Swerdlow SH; Gibson SE
    Am J Surg Pathol; 2018 Mar; 42(3):342-350. PubMed ID: 29309299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.
    Govindan SV; Goldenberg DM; Elsamra SE; Griffiths GL; Ong GL; Brechbiel MW; Burton J; Sgouros G; Mattes MJ
    J Nucl Med; 2000 Dec; 41(12):2089-97. PubMed ID: 11138697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma.
    Roncador G; García Verdes-Montenegro JF; Tedoldi S; Paterson JC; Klapper W; Ballabio E; Maestre L; Pileri S; Hansmann ML; Piris MA; Mason DY; Marafioti T
    Haematologica; 2007 Aug; 92(8):1059-66. PubMed ID: 17640856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution and prognosis of WHO lymphoma subtypes in Taiwan reveals a low incidence of germinal-center derived tumors.
    Chang KC; Huang GC; Jones D; Tsao CJ; Lee JY; Su IJ
    Leuk Lymphoma; 2004 Jul; 45(7):1375-84. PubMed ID: 15359636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
    Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
    Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TOX expression in cutaneous B-cell lymphomas.
    Schrader AM; Jansen PM; Willemze R
    Arch Dermatol Res; 2016 Aug; 308(6):423-7. PubMed ID: 27180090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BAFF-R is expressed on B-cell lymphomas depending on their origin, and is related to proliferation index of nodal diffuse large B-cell lymphomas.
    Takahata H; Ohara N; Ichimura K; Tanaka T; Sato Y; Morito T; Takata K; Kojima M; Kobata T; Yoshino T
    J Clin Exp Hematop; 2010; 50(2):121-7. PubMed ID: 21123970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
    Nguyen PL; Harris NL; Ritz J; Robertson MJ
    Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bcl-2 oncoprotein is widespread in lymphoid tissue and lymphomas but its differential expression in benign versus malignant follicles and monocytoid B-cell proliferations is of diagnostic value.
    Wang T; Lasota J; Hanau CA; Miettinen M
    APMIS; 1995 Sep; 103(9):655-62. PubMed ID: 7488387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor.
    Freeman GJ; Cardoso AA; Boussiotis VA; Anumanthan A; Groves RW; Kupper TS; Clark EA; Nadler LM
    J Immunol; 1998 Sep; 161(6):2708-15. PubMed ID: 9743327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas-Implications for Therapy.
    Tse E; Kwong YL
    Curr Hematol Malig Rep; 2018 Feb; 13(1):37-43. PubMed ID: 29396703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.